| General Information | |
|---|---|
| ZINC ID | ZINC000028702463 |
| Molecular Weight (Da) | 414 |
| SMILES | O=C(NC1CCCCC1)c1cn(-c2ccc(Cl)cc2)c(-c2ccccc2Cl)n1 |
| Molecular Formula | C22Cl2N3O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 111.094 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 28 |
| LogP | 6.066 |
| Activity (Ki) in nM | 2290.868 |
| Polar Surface Area (PSA) | 46.92 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.2 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.27 |
| Ilogp | 4.31 |
| Xlogp3 | 6.01 |
| Wlogp | 5.91 |
| Mlogp | 4.49 |
| Silicos-it log p | 5.03 |
| Consensus log p | 5.15 |
| Esol log s | -6.31 |
| Esol solubility (mg/ml) | 0.000201 |
| Esol solubility (mol/l) | 0.00000048 |
| Esol class | Poorly sol |
| Ali log s | -6.77 |
| Ali solubility (mg/ml) | 0.0000699 |
| Ali solubility (mol/l) | 0.00000016 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.02 |
| Silicos-it solubility (mg/ml) | 0.00000394 |
| Silicos-it solubility (mol/l) | 9.51E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.56 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.04 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.632 |
| Logd | 4.249 |
| Logp | 5.841 |
| F (20%) | 0.009 |
| F (30%) | 0.915 |
| Mdck | 7.14E-06 |
| Ppb | 0.9813 |
| Vdss | 1.251 |
| Fu | 0.0094 |
| Cyp1a2-inh | 0.694 |
| Cyp1a2-sub | 0.157 |
| Cyp2c19-inh | 0.875 |
| Cyp2c19-sub | 0.077 |
| Cl | 2.058 |
| T12 | 0.023 |
| H-ht | 0.471 |
| Dili | 0.918 |
| Roa | 0.523 |
| Fdamdd | 0.921 |
| Skinsen | 0.105 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.417 |
| Bcf | 1.72 |
| Igc50 | 4.685 |
| Lc50 | 5.312 |
| Lc50dm | 5.269 |
| Nr-ar | 0.027 |
| Nr-ar-lbd | 0.011 |
| Nr-ahr | 0.55 |
| Nr-aromatase | 0.814 |
| Nr-er | 0.692 |
| Nr-er-lbd | 0.012 |
| Nr-ppar-gamma | 0.459 |
| Sr-are | 0.892 |
| Sr-atad5 | 0.737 |
| Sr-hse | 0.372 |
| Sr-mmp | 0.834 |
| Sr-p53 | 0.867 |
| Vol | 403.317 |
| Dense | 1.024 |
| Flex | 0.208 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 2 |
| Qed | 0.577 |
| Synth | 2.2 |
| Fsp3 | 0.273 |
| Mce-18 | 51 |
| Natural product-likeness | -1.353 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |